Fig. 5.

5-Aza prevented BaP-induced gastric tumour development in a Bcl6b–dependent manner. (a, b) Representative images showing gross morphology (Scale bar, 5 mm) (a) and H&E staining (Scale bar, 100 μm) (b) of stomachs harbouring BaP-induced tumours (25 week) from Bcl6b^−/− mice and WT controls with or without 5-Aza treatment. The gastric tumour granules were indicated by red arrows. (c-e) Tumour number (c), maximal size (d), and tumour incidence (e) in stomachs from WT and Bcl6b^−/− mice after intragastric administration of BaP (25 week) with or without 5-Aza treatment. (f) Representative images and quantification of Ki-67-immunopositive cells in Bap-induced gastric tumours (25 week) from Bcl6b^−/− mice and WT controls with or without 5-Aza treatment. Scale bar, 50 μm. Data are presented as the mean ± SD; n = 8 per group. *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant; unpaired two-tailed Student’s t tests